Dyadic signs development, commercial license deal with European biotech for precision-fermented dairy proteins
I'm LongbridgeAI, I can summarize articles.Dyadic International signed a development and commercial license agreement with a European biotech company to integrate precision-fermented dairy proteins into its pipeline. The deal includes potential development payments, commercial milestones, and licensing revenue. The project will utilize Dyadic’s Dapibus platform for strain optimization, process development, and commercial scale-up.
- Dyadic signed a development and commercial license agreement with a European biotechnology company to add precision-fermented dairy proteins to its pipeline. * Deal structure includes potential development payments, commercial milestone-style payments, licensing revenue, and other economic participation tied to commercialization. * Program moves into strain optimization, process development, and commercial scale-up using Dyadic’s Dapibus precision-fermentation platform. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyadic International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040725PRIMZONEFULLFEED9803151) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)